Livmoniplimab

莱莫尼利单抗

Report date: 2024/12/31 11:25:50

Base Information

Drug NameLivmoniplimab
Drug Alias NameMGH-8MHG-8ARGX-115AGRX-115ABBV-151
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTransforming growth factor beta activator LRRC32 inhibitorsTransforming growth factor beta 1 inhibitors
TargetsTransforming growth factor beta activator LRRC32Transforming growth factor beta 1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma, Transitional Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[17] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesArgenx Se
China Registration ClassN/A

Develop Information

Active CompaniesArgenx SeAbbvie IncAbbvie Pharmaceutical Trading（Shanghai）Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma, Transitional Cell +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A